Can cutting off doctors’ access to drug company sales representatives make patients more likely to receive a prescription for a dangerous or ineffective drug? A new study led by Temple Fox School of Business Professor George Chressanthis found that doctors who rarely or never meet with pharmaceutical reps are much slower to drop medicines with the FDA’s “black box” warnings and to adopt first-in-class therapies.